1
1 of 3
- Yale New Haven Hospital20 York StreetNew Haven, CT 06510
- Yale Neurosciences InstituteYale Physicians Building800 Howard Avenue, Ste Lower LevelNew Haven, CT 06519
- Yale New Haven Hospital Saint Raphael Campus1450 Chapel StreetNew Haven, CT 06511
Richard Nowak, MD, MS
Neuromuscular Medicine
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From physicians only
Board Certified in
Neuromuscular Medicine
Biography
Richard Nowak, MD, MS, is the director of the Yale Myasthenia Gravis Clinic, where he treats patients with the chronic, autoimmune condition that causes muscles to tire and weaken easily. He provides personalized treatment strategies for patients suffering from myasthenia gravis and other autoimmune neuromuscular conditions.
In addition, Dr. Nowak works with the Yale Medicine Neuromuscular Medicine Program, which is supported by the Muscular Dystrophy Association (MDA), and is a designated MDA-ALS clinic. The program provides comprehensive diagnostic evaluation, consultation and management for a range of neuromuscular disorders.
An associate professor of neurology at Yale School of Medicine, Dr. Nowak is also a busy researcher who directs the Program in Clinical and Translational Neuromuscular Research at Yale, where his goal is to improve the understanding of autoimmune neuromuscular disorders, identify new drug targets and explore new therapies. In 2013, he was awarded a $4.8 million grant to conduct the first clinical trial for myasthenia gravis sponsored by the National Institutes of Health.
Titles
- Associate Professor of Neurology
- Director, Program in Clinical & Translational Neuromuscular Research
- Director, Yale Myasthenia Gravis Clinic
Education & Training
- FellowshipYale-New Haven Hospital (2012)
- ResidencyYale-New Haven Hospital (2011)
- ResidentYale-New Haven Hospital (2008)
- MDDrexel University College of Medicine (2007)
- MSNorthwestern University (1999)
- BSLoyola University of Chicago (1997)
Additional Information
Board Certifications
- AB of Psychiatry & Neurology, Neuromuscular Medicine (2021)
Publications
- Nowak R, Habib A, Klink A, Muppidi S, Parthan A, Sader S, Balanean A, Gajra A, Howard J. US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization. Drugs - Real World Outcomes 2024, 11: 593-601. PMID: 39470958, PMCID: PMC11589080, DOI: 10.1007/s40801-024-00457-8.
- Baxter L, Hopkins S, O'Connor K, Pham M, Nowak R, Monson N, Blackburn K, Hibbs R, Vernino S, Noviello C. Fluorescence-detection size-exclusion chromatography specifically detects autoantibodies targeting the ganglionic acetylcholine receptor in patients with autoimmune autonomic ganglionopathy. Journal Of Neuroimmunology 2024, 396: 578454. PMID: 39277987, DOI: 10.1016/j.jneuroim.2024.578454.
- Habib A, Klink A, Muppidi S, Parthan A, Sader S, Balanean A, Gajra A, Nowak R, Howard J. United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use. Journal Of Neurology 2024, 271: 6114-6126. PMID: 39052039, PMCID: PMC11377470, DOI: 10.1007/s00415-024-12569-w.
- Roy B, Nowak R. Trial Design and Impact on Study Outcome: Post-hoc Analysis of the BeatMG Study Based on RINOMAX Trial Criteria (P4-11.004). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205956.
- Muppidi S, Lee J, Habib A, Howard J, Klink A, Kielhorn A, Sabatella G, Nowak R. Effectiveness of Eculizumab Treatment by Time from Diagnosis in Patients with Generalized Myasthenia Gravis: A Retrospective Electronic Medical Record Analysis (S15.006). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205156.
- Roy B, Habiabadi F, O’Connor K, Nowak R, Kaminski H. Proteomic Analysis Reveals a Distinct Immunological Signature for Late-onset Myasthenia Gravis (S15.003). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205944.
- Filipek B, Yandamuri S, Obaid A, Thurman J, Makhani N, Nowak R, Guo Y, Lucchinetti C, Flanagan E, Longbrake E, O’Connor K. Phenotypes of B Cells Producing Autoantibodies in MOGAD Patients (N1.002). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000208259.
- Yandamuri S, Filipek B, Lele N, Cohen I, Bennett J, Nowak R, Sotirchos E, Longbrake E, Mace E, O'Connor K. A Noncanonical CD56dimCD16dim/- NK Cell Subset Indicative of Prior Cytotoxic Activity Is Elevated in Patients with Autoantibody-Mediated Neurologic Diseases. The Journal Of Immunology 2024, 212: 785-800. PMID: 38251887, PMCID: PMC10932911, DOI: 10.4049/jimmunol.2300015.
- Antozzi C, Guptill J, Bril V, Gamez J, Meuth S, Nowak R, Quan D, Sevilla T, Jouvin M, Jin J, Karcher K, Ramchandren S, Sun H, Ling L, Zhu Y, Arroyo S, Group F. Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis. Neurology 2023, 102: e207937. PMID: 38165333, PMCID: PMC10962909, DOI: 10.1212/wnl.0000000000207937.
- Nowak R, Breiner A, Bril V, Allen J, Khan S, Levine T, Jacobs D, Sahagian G, Siddiqi Z, Xu J, Macias W, Benatar M, Adams L, Genge A, Habib A, Hinton J, Holmlund T, Jacobs D, Lange D, Nicolle M, Phan H, Silvestri N, Small G, Yegiaian S. Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extension. Annals Of Clinical And Translational Neurology 2023, 11: 194-206. PMID: 38062618, PMCID: PMC10791011, DOI: 10.1002/acn3.51946.
- Pulley M, Macwan S, Nowak R, Mozaffar T, Rodrigues E, Korideck H, Werneburg B, Narayanaswami P. Change in concomitant therapies for generalized myasthenia gravis in patients receiving eculizumab: A retrospective analysis of registry data. Journal Of The Neurological Sciences 2023, 455: 121092. DOI: 10.1016/j.jns.2023.121092.
- Schlatter M, Yandamuri S, O'Connor K, Nowak R, Pham M, Obaid A, Redman C, Provost M, McSweeney P, Pearlman M, Tees M, Bowen J, Nash R, Georges G. Remission of severe myasthenia gravis after autologous stem cell transplantation. Annals Of Clinical And Translational Neurology 2023, 10: 2105-2113. PMID: 37726935, PMCID: PMC10646993, DOI: 10.1002/acn3.51898.
- Zubair A, Rethana M, Ma A, McAlpine L, Abulaban A, Munro B, Patwa H, Nowak R, Roy B. Plasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions. Journal Of Clinical Neuromuscular Disease 2023, 25: 11-17. PMID: 37611265, DOI: 10.1097/cnd.0000000000000439.
- Torabi T, Zubair A, Nowak R, Tseng B, Haims A, Roy B. Leg MRI as a Complementary Diagnostic Tool in the Assessment of Foot Drop. Journal Of Clinical Neuromuscular Disease 2023, 25: 57-58. PMID: 37611274, DOI: 10.1097/cnd.0000000000000433.
- Pham M, Masi G, Patzina R, Obaid A, Oxendine S, Oh S, Payne A, Nowak R, O’Connor K. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathologica 2023, 146: 319-336. PMID: 37344701, PMCID: PMC11380498, DOI: 10.1007/s00401-023-02603-y.
- Yandamuri S, Filipek B, Obaid A, Lele N, Thurman J, Makhani N, Nowak R, Guo Y, Lucchinetti C, Flanagan E, Longbrake E, O’Connor K. MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity. JCI Insight 2023, 8: e165373. PMID: 37097758, PMCID: PMC10393237, DOI: 10.1172/jci.insight.165373.
- Jiang R, Roy B, Wu Q, Mohanty S, Nowak R, Shaw A, Kleinstein S, O’Connor K. The Plasma Cell Infiltrate Populating the Muscle Tissue of Patients with Inclusion Body Myositis Features Distinct B Cell Receptor Repertoire Properties. ImmunoHorizons 2023, 7: 310-322. PMID: 37171806, PMCID: PMC10579972, DOI: 10.4049/immunohorizons.2200078.
- Masi G, Pham M, Dai Y, Li Y, Karatz T, Oxendine S, Juel V, Ring A, Nowak R, Guptill J, O’Connor K. Investigating Autoantibody Profiles in Seronegative Myasthenia Gravis (P1-5.005). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000202639.
- Pulley M, Macwan S, Nowak R, Mozaffar T, Rodrigues E, Korideck H, Werneburg B, Narayanaswami P. Change in Concomitant Therapies for Generalized Myasthenia Gravis in Patients Receiving Eculizumab: a Retrospective Analysis of Registry Data (P1-5.002). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000202372.
- Roy B, Obaid A, Ohashi S, Coppola C, Das S, Hernandez A, Masi G, Martin-Aguilar L, Lleixà M, Nowak R, Querol Gutierrez L, O’Connor K. Early B cell tolerance defects in anti-neurofascin 155 mediated chronic inflammatory demyelinating polyneuropathy (S40.005). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000203364.
- Guptill J, Benatar M, Granit V, Habib A, Howard J, Barnett-Tapia C, Nowak R, Lee I, Ruzhansky K, Dimachkie M, Cutter G, Kaminski H, Group F. Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials. Neurology 2023, 101: 442-451. PMID: 37076302, PMCID: PMC10491448, DOI: 10.1212/wnl.0000000000207278.
- Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravisMasi G, Pham M, Karatz T, Oh S, Payne A, Nowak R, Howard J, Guptill J, Juel V, O'Connor K. Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis. Annals Of Clinical And Translational Neurology 2023, 10: 825-831. PMID: 36924454, PMCID: PMC10187728, DOI: 10.1002/acn3.51761.
- Ramchandren S, Guptill J, Antozzi C, Bril V, Gamez J, Meuth S, Nowak R, Quan D, Mantecon M, Ling L, Zhu Y, Karcher K, Sun H. Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates With Clinical Improvement in Generalized Myasthenia Gravis Patients. Neurology 2022, 99: s35-s37. DOI: 10.1212/01.wnl.0000903304.73134.e3.
- Fichtner ML, Hoehn KB, Ford EE, Mane-Damas M, Oh S, Waters P, Payne AS, Smith ML, Watson CT, Losen M, Martinez-Martinez P, Nowak RJ, Kleinstein SH, O’Connor K. Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy. Acta Neuropathologica Communications 2022, 10: 154. PMID: 36307868, PMCID: PMC9617453, DOI: 10.1186/s40478-022-01454-0.
- Zubair A, Roy B, Baehring J, Nowak R. Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management. Cureus 2022, 14: e30638. PMID: 36439604, PMCID: PMC9683636, DOI: 10.7759/cureus.30638.
- Guptill J, Nowak R, Guidon A, Howard J, Soliven B, Hammett A, Sheldon B, Li Y, Meece T, Aban I, Cutter G, Kaminski H. A prospective natural history study and biorepository for patients with myasthenia gravis (EXPLORE-MG2) (P6-13.005). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.2269.
- Guptill J, Antozzi C, Bril V, Gamez J, Meuth S, Nowak R, Quan D, Sevilla T, Ling L, Zhu Y, Karcher K, Ramchandren S, Sun H. Serum IgG and Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates with Improvement in MG-ADL in Generalized Myasthenia Patients (S25.007). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.407.
- Habib A, Klink A, Muppidi S, Parthan A, Sader C, Balanean A, Gajra A, Nowak R, Howard J. Real-World Eculizumab Effectiveness on US Patient Outcomes in Myasthenia Gravis (ELEVATE): a Retrospective Chart Review (S41.010). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.868.
- Narayanaswami P, Cutter G, Nowak R, Greene E, Muppidi S, Mozaffar T, Rodrigues E, Korideck H, Howard J. Real-world experience of eculizumab treatment for generalized myasthenia gravis: initial data from a registry of patients with generalized myasthenia gravis in the USA (S25.006). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1320.
- Rethana M, Zubair A, Ma A, McAlpine L, Abulaban A, Nowak R, Roy B. Intravenous Immune Globulins vs Plasma Exchange Usage in Patients with Neuromuscular and Neuro-immunological Conditions (P4-13.007). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.2392.
- Benatar M, Breiner A, Bril V, Nowak R, Dunn I, Jacobs A. Topline Results of a Phase 2 Study of Subcutaneous IMVT-1401 in Patients with Generalized Myasthenia Gravis (1417). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.1417.
- Muppidi S, Klink A, Parthan A, Sader S, Balanean A, Gajra A, Nowak R, Howard J. Real-World Use of Eculizumab in Generalized Myasthenia Gravis in the United States: Results From a Pilot Retrospective Chart-Review Study (1917). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.1917.
- Guptill J, Antozzi C, Bril V, Gamez J, Meuth S, Blanco J, Nowak R, Quan D, Sevilla T, Szczudlik A, Hegarty B, Jouvin M, Jin J, Arroyo S. Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.2157.
- Castillo Y, Tejedor I, Keung B, Tseng B, Nowak R, Roy B. Clinical Characteristics of TS-HDS and FGFR3 Antibodies in Chronic Inflammatory Neuropathies (5171). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.5171.
- Roy B, Kovvuru S, Castillo Y, Huttner A, Nowak R. Reply to: What is the pattern of the neuropathy associated with anti‐FGFR3 antibodies? European Journal Of Neurology 2020, 27: e59-e59. PMID: 32503081, DOI: 10.1111/ene.14381.
- Howard JF, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ, Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar M, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib A, Mathew V, Mozaffar T, Hinton J, Hewitt W, Barnett D, Sullivan P, Ho D, Howard J, Traub R, Chopra M, Kaminski H, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatri B, Lindman E, Olapo T, Sershon L, Lisak R, Bernitsas E, Jia K, Malik R, Lewis-Collins T, Nicolle M, Nowak R, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe G, Silvestri N, Patrick K, Zakalik K, Duda P, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis. JAMA Neurology 2020, 77: 582-592. PMID: 32065623, PMCID: PMC7042797, DOI: 10.1001/jamaneurol.2019.5125.
- Fichtner M, Vieni C, Redler R, Jiang R, Suarez P, Nowak R, Burden S, Bhabha G, Ekiert D, O’Connor K. Monovalent IgG4 autoantibodies require self-antigen driven affinity maturation to acquire pathogenic capacity. The Journal Of Immunology 2020, 204: 224.39-224.39. DOI: 10.4049/jimmunol.204.supp.224.39.
- Roy B, Rutkove S, Qi K, Nowak R. Application of electrical impedance myography to capture disease progression in inclusion body myositis (5330). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.5330.
- Group I, Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard J, Illa I, Mantegazza R, Murai H, Utsugisawa K, Vissing J, Wiendl H, Nowak R. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. Journal Of The Neurological Sciences 2020, 412: 116803. PMID: 32247193, PMCID: PMC7105910, DOI: 10.1016/j.jns.2020.116803.
- Kovvuru S, Cardenas Y, Huttner A, Nowak R, Roy B. Clinical characteristics of fibroblast growth factor receptor 3 antibody‐related polyneuropathy: a retrospective study. European Journal Of Neurology 2020, 27: 1310-1318. PMID: 32068339, DOI: 10.1111/ene.14180.
- Genge A, Jacob S, Murai H, Utsugisawa K, Nowak R, Wiendl H, Fujita K, O’Brien F, Howard J. P.026 Response to eculizumab in patients with myasthenia gravis recently treated with chronic intravenous immunoglobulin. Canadian Journal Of Neurological Sciences / Journal Canadien Des Sciences Neurologiques 2019, 46: s20-s21. DOI: 10.1017/cjn.2019.126.
- Siddiqi Z, Howard J, Jacob S, Guptill J, Meisel A, Wiendl H, Murai H, Utsugisawa K, Nowak R, Fujita K, O’Brien F, Patra K, Muppidi S. A.01 Relieving the burden of myasthenia gravis: eculizumab reduces exacerbation, hospitalization and rescue therapy rates. Canadian Journal Of Neurological Sciences / Journal Canadien Des Sciences Neurologiques 2019, 46: s8-s8. DOI: 10.1017/cjn.2019.83.
- Roy B, Rutkove S, Nowak R. Application of electrical impedance myography (EIM) as a potential biomarker of Inclusion Body Myositis (IBM): A pilot study (P3.4-001). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.p3.4-001.
- Sharma A, Roy B, Khokhar B, Nowak R. Burden of Disease in Patients with Refractory Myasthenia Gravis (P5.4-037). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.p5.4-037.
- Howard J, Kaminski H, Nowak R, Wolfe G, Benatar M, Ricardo A, Hoarty M, DeMarco S, Farzaneh-Far R, Duda P. RA101495, A Subcutaneously Administered Peptide Inhibitor of Complement Component 5 (C5) for the Treatment of Generalized Myasthenia Gravis (gMG): Phase 1 Results and Phase 2 Design (S31.006). Neurology 2018, 90 DOI: 10.1212/wnl.90.15_supplement.s31.006.
- Chan D, Chan A, Farooque P, Nowak R. The Vertebral Body Infarct Sign: A Case of Thoracic Spinal Cord Ischemic Stroke (P3.292). Neurology 2017, 88 DOI: 10.1212/wnl.88.16_supplement.p3.292.
- Allen J, Gelinas D, Lewis R, Nowak R, Wolfe G. Optimizing the Use of Outcome Measures in Chronic Inflammatory Demyelinating Polyneuropathy. TouchREVIEWS In Neurology 2017, 13: 26. DOI: 10.17925/usn.2017.13.01.26.
- Lau K, Kumar A, Yang I, Nowak R. A Case of Myasthenia Gravis Exacerbation in a Patient with Melanoma Treated with Pembrolizumab (P3.138). Neurology 2016, 86 DOI: 10.1212/wnl.86.16_supplement.p3.138.
- Stathopoulos P, Lee J, Gupta S, Shan J, Cotzomi E, Barohn R, Dimachkie M, Querol L, Morbach H, Bannock J, Lee C, Waters P, Nowak R, O'Connor K. The Compromised Fidelity of B Cell Tolerance Checkpoints Contributes to Autoimmunity in Myasthenia Gravis (P5.034). Neurology 2016, 86 DOI: 10.1212/wnl.86.16_supplement.p5.034.
- Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa E, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM, Hehir MK, Hobson-Webb L, Howard JF, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou J, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon J, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4‐diaminopyridine. Muscle & Nerve 2015, 53: 165-168. PMID: 26662952, DOI: 10.1002/mus.25009.
- Benatar M, McDermott M, Sanders D, Wolfe G, Barohn R, Nowak R, Hehir M, Juel V, Katzberg H, Tawil A. Effectiveness of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) (P7.048). Neurology 2015, 84 DOI: 10.1212/wnl.84.14_supplement.p7.048.
- Homafar H, Lakraj A, Nowak R, Robeson K, Goldstein J, Patwa H, DiCapua D. The Relationship Between Cerebrospinal Fluid Protein Levels and Electrophysiologic Abnormalities in Guillain-Barré Syndrome (P7.091). Neurology 2015, 84 DOI: 10.1212/wnl.84.14_supplement.p7.091.
- Cao Y, Dominguez-Villar M, Amezquita R, Liu S, Kleinstein S, Goldstein J, Nowak R, O'Connor K. Pathogenic Antigen-Specific Th17 Cells Drive Autoimmunity Myasthenia Gravis (P1.059). Neurology 2014, 82 DOI: 10.1212/wnl.82.10_supplement.p1.059.
- Robeson K, Keung B, DiCapua D, Goldstein J, O'Connor K, Nowak R. Is the Rituximab Response in Acetylcholine Receptor Autoantibody Myasthenia Gravis Durable? (S36.009). Neurology 2014, 82 DOI: 10.1212/wnl.82.10_supplement.s36.009.
- Nowak R, Keung B, Robeson K, DiCapua D, Goldstein J. Long Term Efficacy of Rituximab in Patients with MuSK Auto-Antibody Myasthenia Gravis (PD6.007). Neurology 2012, 78: pd6.007-pd6.007. DOI: 10.1212/wnl.78.1_meetingabstracts.pd6.007.
- Nowak RJ, DiCapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Therapeutic Advances In Neurological Disorders 2011, 4: 259-266. PMID: 22010039, PMCID: PMC3187675, DOI: 10.1177/1756285611411503.
- Nowak RJ, Cuny GD, Choi S, Lansbury PT, Ray SS. Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. Journal Of Medicinal Chemistry 2010, 53: 2709-18. PMID: 20232802, PMCID: PMC2881568, DOI: 10.1021/jm901062p.
- Ray SS, Nowak RJ, Brown RH, Lansbury PT. Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proceedings Of The National Academy Of Sciences Of The United States Of America 2005, 102: 3639-44. PMID: 15738401, PMCID: PMC553303, DOI: 10.1073/pnas.0408277102.
- Ray SS, Nowak RJ, Strokovich K, Brown RH, Walz T, Lansbury PT. An Intersubunit Disulfide Bond Prevents in Vitro Aggregation of a Superoxide Dismutase-1 Mutant Linked to Familial Amytrophic Lateral Sclerosis †. Biochemistry 2004, 43: 4899-4905. PMID: 15109247, DOI: 10.1021/bi030246r.
- Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 2003, 42: 12749-60. PMID: 14596589, DOI: 10.1021/bi030029q.
- Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT. α-Synuclein, Especially the Parkinson's Disease-associated Mutants, Forms Pore-like Annular and Tubular Protofibrils. Journal Of Molecular Biology 2002, 322: 1089-1102. PMID: 12367530, DOI: 10.1016/s0022-2836(02)00735-0.
- Anguiano M, Nowak RJ, Lansbury PT. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 2002, 41: 11338-43. PMID: 12234175, DOI: 10.1021/bi020314u.
Departments and Programs
Locations
1
1 of 3
- Yale New Haven Hospital20 York StreetNew Haven, CT 06510
- Yale Neurosciences InstituteYale Physicians Building800 Howard Avenue, Ste Lower LevelNew Haven, CT 06519
- Yale New Haven Hospital Saint Raphael Campus1450 Chapel StreetNew Haven, CT 06511
Biography
Richard Nowak, MD, MS, is the director of the Yale Myasthenia Gravis Clinic, where he treats patients with the chronic, autoimmune condition that causes muscles to tire and weaken easily. He provides personalized treatment strategies for patients suffering from myasthenia gravis and other autoimmune neuromuscular conditions.
In addition, Dr. Nowak works with the Yale Medicine Neuromuscular Medicine Program, which is supported by the Muscular Dystrophy Association (MDA), and is a designated MDA-ALS clinic. The program provides comprehensive diagnostic evaluation, consultation and management for a range of neuromuscular disorders.
An associate professor of neurology at Yale School of Medicine, Dr. Nowak is also a busy researcher who directs the Program in Clinical and Translational Neuromuscular Research at Yale, where his goal is to improve the understanding of autoimmune neuromuscular disorders, identify new drug targets and explore new therapies. In 2013, he was awarded a $4.8 million grant to conduct the first clinical trial for myasthenia gravis sponsored by the National Institutes of Health.
Titles
- Associate Professor of Neurology
- Director, Program in Clinical & Translational Neuromuscular Research
- Director, Yale Myasthenia Gravis Clinic
Education & Training
- FellowshipYale-New Haven Hospital (2012)
- ResidencyYale-New Haven Hospital (2011)
- ResidentYale-New Haven Hospital (2008)
- MDDrexel University College of Medicine (2007)
- MSNorthwestern University (1999)
- BSLoyola University of Chicago (1997)
Additional Information
Board Certifications
- AB of Psychiatry & Neurology, Neuromuscular Medicine (2021)
Publications
- Nowak R, Habib A, Klink A, Muppidi S, Parthan A, Sader S, Balanean A, Gajra A, Howard J. US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization. Drugs - Real World Outcomes 2024, 11: 593-601. PMID: 39470958, PMCID: PMC11589080, DOI: 10.1007/s40801-024-00457-8.
- Baxter L, Hopkins S, O'Connor K, Pham M, Nowak R, Monson N, Blackburn K, Hibbs R, Vernino S, Noviello C. Fluorescence-detection size-exclusion chromatography specifically detects autoantibodies targeting the ganglionic acetylcholine receptor in patients with autoimmune autonomic ganglionopathy. Journal Of Neuroimmunology 2024, 396: 578454. PMID: 39277987, DOI: 10.1016/j.jneuroim.2024.578454.
- Habib A, Klink A, Muppidi S, Parthan A, Sader S, Balanean A, Gajra A, Nowak R, Howard J. United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use. Journal Of Neurology 2024, 271: 6114-6126. PMID: 39052039, PMCID: PMC11377470, DOI: 10.1007/s00415-024-12569-w.
- Roy B, Nowak R. Trial Design and Impact on Study Outcome: Post-hoc Analysis of the BeatMG Study Based on RINOMAX Trial Criteria (P4-11.004). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205956.
- Muppidi S, Lee J, Habib A, Howard J, Klink A, Kielhorn A, Sabatella G, Nowak R. Effectiveness of Eculizumab Treatment by Time from Diagnosis in Patients with Generalized Myasthenia Gravis: A Retrospective Electronic Medical Record Analysis (S15.006). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205156.
- Roy B, Habiabadi F, O’Connor K, Nowak R, Kaminski H. Proteomic Analysis Reveals a Distinct Immunological Signature for Late-onset Myasthenia Gravis (S15.003). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205944.
- Filipek B, Yandamuri S, Obaid A, Thurman J, Makhani N, Nowak R, Guo Y, Lucchinetti C, Flanagan E, Longbrake E, O’Connor K. Phenotypes of B Cells Producing Autoantibodies in MOGAD Patients (N1.002). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000208259.
- Yandamuri S, Filipek B, Lele N, Cohen I, Bennett J, Nowak R, Sotirchos E, Longbrake E, Mace E, O'Connor K. A Noncanonical CD56dimCD16dim/- NK Cell Subset Indicative of Prior Cytotoxic Activity Is Elevated in Patients with Autoantibody-Mediated Neurologic Diseases. The Journal Of Immunology 2024, 212: 785-800. PMID: 38251887, PMCID: PMC10932911, DOI: 10.4049/jimmunol.2300015.
- Antozzi C, Guptill J, Bril V, Gamez J, Meuth S, Nowak R, Quan D, Sevilla T, Jouvin M, Jin J, Karcher K, Ramchandren S, Sun H, Ling L, Zhu Y, Arroyo S, Group F. Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis. Neurology 2023, 102: e207937. PMID: 38165333, PMCID: PMC10962909, DOI: 10.1212/wnl.0000000000207937.
- Nowak R, Breiner A, Bril V, Allen J, Khan S, Levine T, Jacobs D, Sahagian G, Siddiqi Z, Xu J, Macias W, Benatar M, Adams L, Genge A, Habib A, Hinton J, Holmlund T, Jacobs D, Lange D, Nicolle M, Phan H, Silvestri N, Small G, Yegiaian S. Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extension. Annals Of Clinical And Translational Neurology 2023, 11: 194-206. PMID: 38062618, PMCID: PMC10791011, DOI: 10.1002/acn3.51946.
- Pulley M, Macwan S, Nowak R, Mozaffar T, Rodrigues E, Korideck H, Werneburg B, Narayanaswami P. Change in concomitant therapies for generalized myasthenia gravis in patients receiving eculizumab: A retrospective analysis of registry data. Journal Of The Neurological Sciences 2023, 455: 121092. DOI: 10.1016/j.jns.2023.121092.
- Schlatter M, Yandamuri S, O'Connor K, Nowak R, Pham M, Obaid A, Redman C, Provost M, McSweeney P, Pearlman M, Tees M, Bowen J, Nash R, Georges G. Remission of severe myasthenia gravis after autologous stem cell transplantation. Annals Of Clinical And Translational Neurology 2023, 10: 2105-2113. PMID: 37726935, PMCID: PMC10646993, DOI: 10.1002/acn3.51898.
- Zubair A, Rethana M, Ma A, McAlpine L, Abulaban A, Munro B, Patwa H, Nowak R, Roy B. Plasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions. Journal Of Clinical Neuromuscular Disease 2023, 25: 11-17. PMID: 37611265, DOI: 10.1097/cnd.0000000000000439.
- Torabi T, Zubair A, Nowak R, Tseng B, Haims A, Roy B. Leg MRI as a Complementary Diagnostic Tool in the Assessment of Foot Drop. Journal Of Clinical Neuromuscular Disease 2023, 25: 57-58. PMID: 37611274, DOI: 10.1097/cnd.0000000000000433.
- Pham M, Masi G, Patzina R, Obaid A, Oxendine S, Oh S, Payne A, Nowak R, O’Connor K. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathologica 2023, 146: 319-336. PMID: 37344701, PMCID: PMC11380498, DOI: 10.1007/s00401-023-02603-y.
- Yandamuri S, Filipek B, Obaid A, Lele N, Thurman J, Makhani N, Nowak R, Guo Y, Lucchinetti C, Flanagan E, Longbrake E, O’Connor K. MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity. JCI Insight 2023, 8: e165373. PMID: 37097758, PMCID: PMC10393237, DOI: 10.1172/jci.insight.165373.
- Jiang R, Roy B, Wu Q, Mohanty S, Nowak R, Shaw A, Kleinstein S, O’Connor K. The Plasma Cell Infiltrate Populating the Muscle Tissue of Patients with Inclusion Body Myositis Features Distinct B Cell Receptor Repertoire Properties. ImmunoHorizons 2023, 7: 310-322. PMID: 37171806, PMCID: PMC10579972, DOI: 10.4049/immunohorizons.2200078.
- Masi G, Pham M, Dai Y, Li Y, Karatz T, Oxendine S, Juel V, Ring A, Nowak R, Guptill J, O’Connor K. Investigating Autoantibody Profiles in Seronegative Myasthenia Gravis (P1-5.005). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000202639.
- Pulley M, Macwan S, Nowak R, Mozaffar T, Rodrigues E, Korideck H, Werneburg B, Narayanaswami P. Change in Concomitant Therapies for Generalized Myasthenia Gravis in Patients Receiving Eculizumab: a Retrospective Analysis of Registry Data (P1-5.002). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000202372.
- Roy B, Obaid A, Ohashi S, Coppola C, Das S, Hernandez A, Masi G, Martin-Aguilar L, Lleixà M, Nowak R, Querol Gutierrez L, O’Connor K. Early B cell tolerance defects in anti-neurofascin 155 mediated chronic inflammatory demyelinating polyneuropathy (S40.005). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000203364.
- Guptill J, Benatar M, Granit V, Habib A, Howard J, Barnett-Tapia C, Nowak R, Lee I, Ruzhansky K, Dimachkie M, Cutter G, Kaminski H, Group F. Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials. Neurology 2023, 101: 442-451. PMID: 37076302, PMCID: PMC10491448, DOI: 10.1212/wnl.0000000000207278.
- Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravisMasi G, Pham M, Karatz T, Oh S, Payne A, Nowak R, Howard J, Guptill J, Juel V, O'Connor K. Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis. Annals Of Clinical And Translational Neurology 2023, 10: 825-831. PMID: 36924454, PMCID: PMC10187728, DOI: 10.1002/acn3.51761.
- Ramchandren S, Guptill J, Antozzi C, Bril V, Gamez J, Meuth S, Nowak R, Quan D, Mantecon M, Ling L, Zhu Y, Karcher K, Sun H. Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates With Clinical Improvement in Generalized Myasthenia Gravis Patients. Neurology 2022, 99: s35-s37. DOI: 10.1212/01.wnl.0000903304.73134.e3.
- Fichtner ML, Hoehn KB, Ford EE, Mane-Damas M, Oh S, Waters P, Payne AS, Smith ML, Watson CT, Losen M, Martinez-Martinez P, Nowak RJ, Kleinstein SH, O’Connor K. Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy. Acta Neuropathologica Communications 2022, 10: 154. PMID: 36307868, PMCID: PMC9617453, DOI: 10.1186/s40478-022-01454-0.
- Zubair A, Roy B, Baehring J, Nowak R. Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management. Cureus 2022, 14: e30638. PMID: 36439604, PMCID: PMC9683636, DOI: 10.7759/cureus.30638.
- Guptill J, Nowak R, Guidon A, Howard J, Soliven B, Hammett A, Sheldon B, Li Y, Meece T, Aban I, Cutter G, Kaminski H. A prospective natural history study and biorepository for patients with myasthenia gravis (EXPLORE-MG2) (P6-13.005). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.2269.
- Guptill J, Antozzi C, Bril V, Gamez J, Meuth S, Nowak R, Quan D, Sevilla T, Ling L, Zhu Y, Karcher K, Ramchandren S, Sun H. Serum IgG and Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates with Improvement in MG-ADL in Generalized Myasthenia Patients (S25.007). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.407.
- Habib A, Klink A, Muppidi S, Parthan A, Sader C, Balanean A, Gajra A, Nowak R, Howard J. Real-World Eculizumab Effectiveness on US Patient Outcomes in Myasthenia Gravis (ELEVATE): a Retrospective Chart Review (S41.010). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.868.
- Narayanaswami P, Cutter G, Nowak R, Greene E, Muppidi S, Mozaffar T, Rodrigues E, Korideck H, Howard J. Real-world experience of eculizumab treatment for generalized myasthenia gravis: initial data from a registry of patients with generalized myasthenia gravis in the USA (S25.006). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1320.
- Rethana M, Zubair A, Ma A, McAlpine L, Abulaban A, Nowak R, Roy B. Intravenous Immune Globulins vs Plasma Exchange Usage in Patients with Neuromuscular and Neuro-immunological Conditions (P4-13.007). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.2392.
- Benatar M, Breiner A, Bril V, Nowak R, Dunn I, Jacobs A. Topline Results of a Phase 2 Study of Subcutaneous IMVT-1401 in Patients with Generalized Myasthenia Gravis (1417). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.1417.
- Muppidi S, Klink A, Parthan A, Sader S, Balanean A, Gajra A, Nowak R, Howard J. Real-World Use of Eculizumab in Generalized Myasthenia Gravis in the United States: Results From a Pilot Retrospective Chart-Review Study (1917). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.1917.
- Guptill J, Antozzi C, Bril V, Gamez J, Meuth S, Blanco J, Nowak R, Quan D, Sevilla T, Szczudlik A, Hegarty B, Jouvin M, Jin J, Arroyo S. Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.2157.
- Castillo Y, Tejedor I, Keung B, Tseng B, Nowak R, Roy B. Clinical Characteristics of TS-HDS and FGFR3 Antibodies in Chronic Inflammatory Neuropathies (5171). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.5171.
- Roy B, Kovvuru S, Castillo Y, Huttner A, Nowak R. Reply to: What is the pattern of the neuropathy associated with anti‐FGFR3 antibodies? European Journal Of Neurology 2020, 27: e59-e59. PMID: 32503081, DOI: 10.1111/ene.14381.
- Howard JF, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ, Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar M, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib A, Mathew V, Mozaffar T, Hinton J, Hewitt W, Barnett D, Sullivan P, Ho D, Howard J, Traub R, Chopra M, Kaminski H, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatri B, Lindman E, Olapo T, Sershon L, Lisak R, Bernitsas E, Jia K, Malik R, Lewis-Collins T, Nicolle M, Nowak R, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe G, Silvestri N, Patrick K, Zakalik K, Duda P, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis. JAMA Neurology 2020, 77: 582-592. PMID: 32065623, PMCID: PMC7042797, DOI: 10.1001/jamaneurol.2019.5125.
- Fichtner M, Vieni C, Redler R, Jiang R, Suarez P, Nowak R, Burden S, Bhabha G, Ekiert D, O’Connor K. Monovalent IgG4 autoantibodies require self-antigen driven affinity maturation to acquire pathogenic capacity. The Journal Of Immunology 2020, 204: 224.39-224.39. DOI: 10.4049/jimmunol.204.supp.224.39.
- Roy B, Rutkove S, Qi K, Nowak R. Application of electrical impedance myography to capture disease progression in inclusion body myositis (5330). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.5330.
- Group I, Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard J, Illa I, Mantegazza R, Murai H, Utsugisawa K, Vissing J, Wiendl H, Nowak R. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. Journal Of The Neurological Sciences 2020, 412: 116803. PMID: 32247193, PMCID: PMC7105910, DOI: 10.1016/j.jns.2020.116803.
- Kovvuru S, Cardenas Y, Huttner A, Nowak R, Roy B. Clinical characteristics of fibroblast growth factor receptor 3 antibody‐related polyneuropathy: a retrospective study. European Journal Of Neurology 2020, 27: 1310-1318. PMID: 32068339, DOI: 10.1111/ene.14180.
- Genge A, Jacob S, Murai H, Utsugisawa K, Nowak R, Wiendl H, Fujita K, O’Brien F, Howard J. P.026 Response to eculizumab in patients with myasthenia gravis recently treated with chronic intravenous immunoglobulin. Canadian Journal Of Neurological Sciences / Journal Canadien Des Sciences Neurologiques 2019, 46: s20-s21. DOI: 10.1017/cjn.2019.126.
- Siddiqi Z, Howard J, Jacob S, Guptill J, Meisel A, Wiendl H, Murai H, Utsugisawa K, Nowak R, Fujita K, O’Brien F, Patra K, Muppidi S. A.01 Relieving the burden of myasthenia gravis: eculizumab reduces exacerbation, hospitalization and rescue therapy rates. Canadian Journal Of Neurological Sciences / Journal Canadien Des Sciences Neurologiques 2019, 46: s8-s8. DOI: 10.1017/cjn.2019.83.
- Roy B, Rutkove S, Nowak R. Application of electrical impedance myography (EIM) as a potential biomarker of Inclusion Body Myositis (IBM): A pilot study (P3.4-001). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.p3.4-001.
- Sharma A, Roy B, Khokhar B, Nowak R. Burden of Disease in Patients with Refractory Myasthenia Gravis (P5.4-037). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.p5.4-037.
- Howard J, Kaminski H, Nowak R, Wolfe G, Benatar M, Ricardo A, Hoarty M, DeMarco S, Farzaneh-Far R, Duda P. RA101495, A Subcutaneously Administered Peptide Inhibitor of Complement Component 5 (C5) for the Treatment of Generalized Myasthenia Gravis (gMG): Phase 1 Results and Phase 2 Design (S31.006). Neurology 2018, 90 DOI: 10.1212/wnl.90.15_supplement.s31.006.
- Chan D, Chan A, Farooque P, Nowak R. The Vertebral Body Infarct Sign: A Case of Thoracic Spinal Cord Ischemic Stroke (P3.292). Neurology 2017, 88 DOI: 10.1212/wnl.88.16_supplement.p3.292.
- Allen J, Gelinas D, Lewis R, Nowak R, Wolfe G. Optimizing the Use of Outcome Measures in Chronic Inflammatory Demyelinating Polyneuropathy. TouchREVIEWS In Neurology 2017, 13: 26. DOI: 10.17925/usn.2017.13.01.26.
- Lau K, Kumar A, Yang I, Nowak R. A Case of Myasthenia Gravis Exacerbation in a Patient with Melanoma Treated with Pembrolizumab (P3.138). Neurology 2016, 86 DOI: 10.1212/wnl.86.16_supplement.p3.138.
- Stathopoulos P, Lee J, Gupta S, Shan J, Cotzomi E, Barohn R, Dimachkie M, Querol L, Morbach H, Bannock J, Lee C, Waters P, Nowak R, O'Connor K. The Compromised Fidelity of B Cell Tolerance Checkpoints Contributes to Autoimmunity in Myasthenia Gravis (P5.034). Neurology 2016, 86 DOI: 10.1212/wnl.86.16_supplement.p5.034.
- Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa E, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM, Hehir MK, Hobson-Webb L, Howard JF, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou J, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon J, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4‐diaminopyridine. Muscle & Nerve 2015, 53: 165-168. PMID: 26662952, DOI: 10.1002/mus.25009.
- Benatar M, McDermott M, Sanders D, Wolfe G, Barohn R, Nowak R, Hehir M, Juel V, Katzberg H, Tawil A. Effectiveness of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) (P7.048). Neurology 2015, 84 DOI: 10.1212/wnl.84.14_supplement.p7.048.
- Homafar H, Lakraj A, Nowak R, Robeson K, Goldstein J, Patwa H, DiCapua D. The Relationship Between Cerebrospinal Fluid Protein Levels and Electrophysiologic Abnormalities in Guillain-Barré Syndrome (P7.091). Neurology 2015, 84 DOI: 10.1212/wnl.84.14_supplement.p7.091.
- Cao Y, Dominguez-Villar M, Amezquita R, Liu S, Kleinstein S, Goldstein J, Nowak R, O'Connor K. Pathogenic Antigen-Specific Th17 Cells Drive Autoimmunity Myasthenia Gravis (P1.059). Neurology 2014, 82 DOI: 10.1212/wnl.82.10_supplement.p1.059.
- Robeson K, Keung B, DiCapua D, Goldstein J, O'Connor K, Nowak R. Is the Rituximab Response in Acetylcholine Receptor Autoantibody Myasthenia Gravis Durable? (S36.009). Neurology 2014, 82 DOI: 10.1212/wnl.82.10_supplement.s36.009.
- Nowak R, Keung B, Robeson K, DiCapua D, Goldstein J. Long Term Efficacy of Rituximab in Patients with MuSK Auto-Antibody Myasthenia Gravis (PD6.007). Neurology 2012, 78: pd6.007-pd6.007. DOI: 10.1212/wnl.78.1_meetingabstracts.pd6.007.
- Nowak RJ, DiCapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Therapeutic Advances In Neurological Disorders 2011, 4: 259-266. PMID: 22010039, PMCID: PMC3187675, DOI: 10.1177/1756285611411503.
- Nowak RJ, Cuny GD, Choi S, Lansbury PT, Ray SS. Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. Journal Of Medicinal Chemistry 2010, 53: 2709-18. PMID: 20232802, PMCID: PMC2881568, DOI: 10.1021/jm901062p.
- Ray SS, Nowak RJ, Brown RH, Lansbury PT. Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proceedings Of The National Academy Of Sciences Of The United States Of America 2005, 102: 3639-44. PMID: 15738401, PMCID: PMC553303, DOI: 10.1073/pnas.0408277102.
- Ray SS, Nowak RJ, Strokovich K, Brown RH, Walz T, Lansbury PT. An Intersubunit Disulfide Bond Prevents in Vitro Aggregation of a Superoxide Dismutase-1 Mutant Linked to Familial Amytrophic Lateral Sclerosis †. Biochemistry 2004, 43: 4899-4905. PMID: 15109247, DOI: 10.1021/bi030246r.
- Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 2003, 42: 12749-60. PMID: 14596589, DOI: 10.1021/bi030029q.
- Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT. α-Synuclein, Especially the Parkinson's Disease-associated Mutants, Forms Pore-like Annular and Tubular Protofibrils. Journal Of Molecular Biology 2002, 322: 1089-1102. PMID: 12367530, DOI: 10.1016/s0022-2836(02)00735-0.
- Anguiano M, Nowak RJ, Lansbury PT. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 2002, 41: 11338-43. PMID: 12234175, DOI: 10.1021/bi020314u.
Departments and Programs
Locations
1
1 of 3
- Yale New Haven Hospital20 York StreetNew Haven, CT 06510
- Yale Neurosciences InstituteYale Physicians Building800 Howard Avenue, Ste Lower LevelNew Haven, CT 06519
- Yale New Haven Hospital Saint Raphael Campus1450 Chapel StreetNew Haven, CT 06511
1
1 of 3
- Yale New Haven Hospital20 York StreetNew Haven, CT 06510
- Yale Neurosciences InstituteYale Physicians Building800 Howard Avenue, Ste Lower LevelNew Haven, CT 06519
- Yale New Haven Hospital Saint Raphael Campus1450 Chapel StreetNew Haven, CT 06511